Mounjaro ‘never to be public funded’ for weight loss, says pharma as diabetes stoush erupts
Mounjaro has been recommended for public funding for diabetes treatment in Australia, but its manufacturer is rejecting the deal amid controversy. The drug's manufacturer is walking away from the deal, sparking a dramatic flashpoint in Australia's medicines wars.
Mounjaro, a diabetes drug, has been recommended for public funding by Australia's independent medicines committee. However, the drug's manufacturer is rejecting the deal, amid a controversy over its potential use for weight loss. The manufacturer has stated that Mounjaro will 'never be public funded' for weight loss. The decision has sparked a dramatic flashpoint in Australia's medicines wars. The controversy highlights the tension between making effective treatments accessible to the public and the interests of pharmaceutical companies.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.